- Understanding COPD Slideshow
- COPD (Chronic Obstructive Pulmonary Disease) Quiz
- Energy Foods for COPD Slideshow Pictures
Does Kinlytic (urokinase) cause side effects?
Kinlytic (urokinase) is a thrombolytic medication used to break up blood clots in the lungs. Urokinase is an enzyme (protein) that disrupts the clotting cycle and breaks down blood clots lodged in the lungs in people with pulmonary embolism.
Common side effects of Kinlytic include:
Serious side effects of Kinlytic include:
- anaphylaxis reactions.
Drug interactions of Kinlytic include other medications that alter platelet function and increase risk of bleeding such as:
- nonsteroidal anti-inflammatory drugs (NSAIDs),
- clopidogrel, and
Kinlytic (urokinase) side effects list for healthcare professionals
The most serious adverse reactions reported with Kinlytic (urokinase injection) administration include:
- fatal hemorrhage and
Bleeding is the most frequent adverse reaction associated with Kinlytic and can be fatal.
In controlled clinical studies using a 12-hour infusion of urokinase for the treatment of pulmonary embolism (UPET and USPET),3,5,6 bleeding resulting in at least a 5% decrease in hematocrit was reported in 52 of 141 urokinase-treated patients.
Significant bleeding events requiring transfusion of greater than 2 units of blood were observed during the 14-day study period in 3 of 141 urokinasetreated patients in these studies.
Multiple bleeding events may have occurred in an individual patient. Most bleeding occurred at sites of external incisions and vascular puncture, with lesser frequency in gastrointestinal, genitourinary, intracranial, retroperitoneal, and intramuscular sites.
Sources of Information on Adverse Reactions
There are limited well-controlled clinical studies performed using urokinase. The adverse reactions described in the following sections reflect both the clinical use of Kinlytic (urokinase injection) in the general population and limited controlled study data.
Because post-marketing reports of adverse reactions are voluntary and the population is of uncertain size, it is not always possible to reliably estimate the frequency of the reaction or establish a causal relationship to drug exposure.
The following allergic-type reactions have been observed in clinical trials and/or post-marketing experience:
Infusion reaction symptoms include:
- fever and/or chills/rigors,
- back pain,
- vomiting, and
Other Adverse Reactions
Other adverse events occurring in patients receiving Kinlytic (urokinase injection) therapy in clinical studies, regardless of causality, include:
- myocardial infarction,
- recurrent pulmonary embolism,
- decreased hematocrit,
- substernal pain,
- thrombocytopenia, and
Additional adverse reactions reported from post-marketing experience include cardiac arrest, vascular embolization (cerebral and distal) including:
- cholesterol emboli,
- cerebral vascular accident,
- pulmonary edema,
- reperfusion ventricular arrhythmias and
- chest pain.
A cause and effect relationship has not been established.
The immunogenicity of Kinlytic (urokinase injection) has not been studied.
What drugs interact with Kinlytic (urokinase)?
Anticoagulants and agents that alter platelet function (such as aspirin, other non-steroidal antiinflammatory agents, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of serious bleeding.
Administration of Kinlytic (urokinase injection) prior to, during, or after thrombolytic agents may increase the risk of serious bleeding.
Because concomitant use of Kinlytic (urokinase injection) with agents that alter coagulation, inhibit platelet function, or are thrombolytic may further increase the potential for bleeding complications, careful monitoring for bleeding is recommended.
The interaction of Kinlytic (urokinase injection) with other drugs has not been studied and is not known.
Kinlytic (urokinase) is a thrombolytic medication used to break up blood clots in the lungs. Urokinase is an enzyme (protein) that disrupts the clotting cycle and breaks down blood clots lodged in the lungs in people with pulmonary embolism. Common side effects of Kinlytic include bleeding, decreased hematocrit, chest pain, increased heart rate, fever, chills, nausea, and vomiting. Serious side effects of Kinlytic include anaphylaxis reactions. There are no adequate studies done on Kinlytic to determine safe and effective use in pregnant women. Kinlytic should be only used during pregnancy if clearly needed. It is unknown if Kinlytic enters breast milk. It is best to be cautious before using it in breastfeeding mothers.
Multimedia: Slideshows, Images & Quizzes
DVT (Deep Vein Thrombosis) and Pulmonary Embolism (PE) Quiz
Take the Deep Vein Thrombosis and Pulmonary Embolism Quiz to learn causes, symptoms, and treatments for these two dangerous...
Picture of Blood Clot
Blood that has been converted from a liquid to a solid state. See a picture of Blood Clot and learn more about the health topic.
Blood Clots: 4 Signs You Could Have One
Blood clots can be deadly medical emergencies that can form in different parts of your body. Learn the warning signs that you...
Related Disease Conditions
Second Source article from Government
Deep Vein Thrombosis (DVT, Blood Clot in the Legs)
Deep vein thrombosis (DVT) is a blood clot in the deep veins, and can be caused by broken bones, trauma to a limb, immobility, medications, smoking, cancer, genetic predisposition, and cancer. Symptoms of a deep vein thrombosis in a leg are swelling, tenderness, redness, warmth, and pain. Treatments for DVT include medications and surgery.
Pulmonary Embolism (Blood Clot in the Lung)
A pulmonary embolism (PE) occurs when a piece of a blood clot from deep vein thrombosis (DVT) breaks off and travels to an artery in the lung where it blocks the artery and damages the lung. The most common symptoms of a pulmonary embolism are shortness of breath, chest pain, and a rapid heart rate. Causes of pulmonary embolism include prolonged immobilization, certain medications, smoking, cancer, pregnancy, and surgery. Pulmonary embolism can cause death if not treated promptly.
Blood Clots (in the Leg)
Blood clots can occur in the venous and arterial vascular system. Blood clots can form in the heart, legs, arteries, veins, bladder, urinary tract and uterus. Risk factors for causes of blood clots include high blood pressure and cholesterol, diabetes, smoking, and family history. Symptoms of a blood clot depend on the location of the clot. Some blood clots are a medical emergency. Blood clots are treated depending upon the cause of the clot. Blood clots can be prevented by lowering the risk factors for developing blood clots.
Treatment & Diagnosis
Medications & Supplements
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Professional side effects and drug interactions sections courtesy of the U.S. Food and Drug Administration.